Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Pre-eclampsia and Future Cardiovascular Health: An Underused Opportunity to Improve Family Health (FINNCARE)

maanantai 28. syyskuuta 2026 päivittänyt: Tiina Jääskeläinen, Helsinki University Central Hospital

Background: PE (pre-eclampsia) is a common pregnancy-specific vascular hypertensive disease affecting 3-5% of pregnancies. PE independently increases the risk for premature cardiovascular disease (CVD) in mothers and their offspring long-term. PE provides a unique window for early risk profiling and CVD prevention. However, the efficacy of a family oriented lifestyle intervention to lower CVD risk in families with history of PE has not previously been evaluated.

Aim: This study will explore the impact of PE on CVD progression 8-12 years from delivery in mothers and their children, and assess whether a lifestyle intervention is useful for lowering mother and child blood pressure and improving the CVD risk profile overall in families with a history of PE.

Hypothesis: PE is related with CVD progression mediated by elevated blood pressure. Blood pressure and the CVD risk profile overall is modifiable in mothers and children by a 12-month behavioral lifestyle intervention in families with a history of PE.

Study design: Randomized controlled behavioral lifestyle intervention trial where families (mother, child and father from the FINNPEC study) are offered the opportunity to participate in a lifestyle intervention program 8-12 years after a PE pregnancy. 300 PE families will be randomized 1:1 to a 12-month lifestyle intervention program or to a control group. A parallel group of 100 non-PE control families will be assessed at baseline and follow-up.

Main outcome: 24 hour mean blood pressure change between baseline and follow-up in mother and child.

Significance: This study will provide information on CVD progression in mothers and children 8-12 years from a PE pregnancy. Furthermore, the study assess the effect of a 12-month lifestyle intervention on blood pressure and CVD risk profile overall following a PE pregnancy. Potentially, the study provides the opportunity to identify PE families at highest risk of CVD progression and families amenable to blood pressure and CVD risk profile improvement.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Power analysis:

Power calculations were performed in order to detect 5.5 mmHg reduction in maternal systolic blood pressure with a power of 80% and a 2-sided p-value of 0.05 for the difference between the groups (intervention and control PE) (NICE 2011). Accounting for a 20% loss to follow-up or missing data, a sample of 148 women in the PE intervention group and 148 women in the PE control group is needed.

Specific objectives:

  1. To assess cardiovascular health and CVD progression in families (mother, child and father) 8-12 years following a PE pregnancy compared with non-PE control families.
  2. To assess the effectiveness of a behavioral 12-month lifestyle intervention in mothers and their children 8-12 years following a PE pregnancy to lower blood pressure and improve their CVD risk profile overall.
  3. To assess the effectiveness of a lifestyle intervention on the awareness of CVD risk after a PE pregnancy.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

284

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

      • Helsinki, Suomi, 00029
        • Helsinki University Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Lapsi
  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Joo

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

Families are recruited from the FINNPEC cohort. In FINNPEC, PE was defined as hypertension and proteinuria occurring after 20 weeks gestation (American College of Obstetricians and Gynecologists 2002 criteria). Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. Proteinuria was defined as urinary excretion of ≥0.3 g protein in a 24-hour specimen, or 0.3 g/L, or two ≥1+ readings on a dipstick in a random urine determination with no evidence of a urinary tract infection. Each PE diagnosis was ascertained based on hospital records and confirmed independently by a research nurse and a study physician in the original FINNPEC case-control study including 1450 nulliparous or multiparous women with a singleton pregnancy with PE and 1065 pregnant control women without PE (aged 18-47 years) from all 5 university hospitals in Finland during 2008-2011.

Exclusion criteria in the FINNPEC: multiple pregnancy, inability to speak Finnish or Swedish.

Exclusion Criteria in the FINNCARE:

  • Pregnancy and/or lactation (for all mothers)
  • Pre-eclampsia in any previous or subsequent pregnancies (for all non-PE mothers)

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: PE intervention

A 12-month lifestyle intervention program to improve mothers and their children blood pressure and CVD risk profile.

Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.

Ei väliintuloa: PE control

The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.

Ei väliintuloa: Non-PE control

The control group continue habitual lifestyle but will perform the same baseline and follow-up measurements as the intervention group. They will be given general written information on healthy eating.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Blood pressure (mothers)
Aikaikkuna: baseline -12 months

mean 24 hour ambulatory systolic BP and diastolic BP; mmHg

baseline -12 months
Blood pressure (children)
Aikaikkuna: baseline -12 months

mean 24 hour ambulatory systolic BP and diastolic BP; mmHg

baseline -12 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Blood pressure 24 hour variability (mothers)
Aikaikkuna: baseline -12 months

nocturnal systolic and diastolic BP dip; standard deviation of systolic and diastolic BP; weighted standard deviation of systolic and diastolic BP; mmHg

baseline -12 months
Arterial stiffness (mothers)
Aikaikkuna: baseline -12 months

carotid-femoral pulse wave velocity; m/s

baseline -12 months
Adiposity BMI (mothers)
Aikaikkuna: baseline -12 months

BMI; kg/m2

baseline -12 months
Adiposity WHR (mothers)
Aikaikkuna: baseline -12 months

waist-hip-ratio (no unit)

baseline -12 months
Adiposity BF% (mothers)
Aikaikkuna: baseline -12 months

body fat percentage; %

baseline -12 months
Dietary intake FAT (mothers)
Aikaikkuna: baseline -12 months

food frequency questionnaire on quality of fat (SFA, MUFA and PUFA; E%/day)

baseline -12 months
Dietary intake FIBER (mothers)
Aikaikkuna: baseline -12 months

food frequency questionnaire on fiber intake; g/day

baseline -12 months
Dietary intake SALT (mothers)
Aikaikkuna: baseline -12 months

food frequency questionnaire on salt intake; g/d

baseline -12 months
Physical activity and sedentary behavior QUEST1 (mothers)
Aikaikkuna: baseline -12 months

questionnaire data: weekly number of sessions and minutes of moderate-to-vigorous-intensity physical activity and walking

baseline -12 months
Physical activity and sedentary behavior QUEST2 (mothers)
Aikaikkuna: baseline -12 months

questionnaire data: meeting physical activity recommendations

baseline -12 months
Physical activity and sedentary behavior QUEST3 (mothers)
Aikaikkuna: baseline -12 months

questionnaire data: daily minutes of sitting on a non-weekend and weekend day

baseline -12 months
Physical activity and sedentary behavior ACTIVITY1 (mothers)
Aikaikkuna: baseline -12 months

accelerometer data: daily number of steps

baseline -12 months
Physical activity and sedentary behavior ACTIVITY2 (mothers)
Aikaikkuna: baseline -12 months

accelerometer data: daily minutes of total and intensity-specific physical activity

baseline -12 months
Physical activity and sedentary behavior ACTIVITY3 (mothers)
Aikaikkuna: baseline -12 months

accelerometer data: daily minutes of stationary behavior

baseline -12 months
Physical activity and sedentary behavior ACTIVITY4 (mothers)
Aikaikkuna: baseline -12 months

accelerometer data: daily number of breaks in stationary behavior

baseline -12 months
Smoking (mothers)
Aikaikkuna: baseline -12 months

questionnaire on status of smoking/use of snuf/use of electronic cigarettes/nicotine replacement therapy and number of cigarettes/day

baseline -12 months
Laboratory assessment of cardiovascular risk LIPIDS (mothers)
Aikaikkuna: baseline -12 months

lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l)

baseline -12 months
Laboratory assessment of cardiovascular risk INFL (mothers)
Aikaikkuna: baseline -12 months

hs-CRP; mg/l

baseline -12 months
Laboratory assessment of cardiovascular risk HOMA (mothers)
Aikaikkuna: baseline -12 months

HOMA index calculated as glucose; mmol/l x insulin; mU/l / 22.5

baseline -12 months
Awareness of later life morbidity (mothers)
Aikaikkuna: baseline -12 months

A brief questionnaire with true or false questions on pre-eclampsia and later life morbidity

baseline -12 months
Arterial stiffness (children)
Aikaikkuna: baseline -12 months

carotid-femoral pulse wave velocity; m/s

baseline -12 months
Adiposity BMI (children)
Aikaikkuna: baseline -12 months

BMI z-score

baseline -12 months
Adiposity WHR (children)
Aikaikkuna: baseline -12 months

waist-hip-ratio (no unit)

baseline -12 months
Adiposity BF% (children)
Aikaikkuna: baseline -12 months

body fat percentage; %

baseline -12 months
Dietary intake FFQ (children)
Aikaikkuna: baseline -12 months

food frequency questionnaire derived data on SFA index, fiber index, salt index (sum of food items rich in SFA/fiber/salt used during the previous week)

baseline -12 months
Physical activity and sedentary behavior QUEST1 (children)
Aikaikkuna: baseline -12 months

questionnaire data: weekly number of days and daily duration of active travel to school and hobbies, structured physical activity outside school hours, unstructured physical activity outside school hours, screen time sitting, non-screen time sitting Accelerometer data: daily number of steps; daily minutes of total and intensity-specific physical activity; daily minutes of and stationary behavior; meeting physical activity recommendations; daily number of breaks in stationary behavior

baseline -12 months
Physical activity and sedentary behavior QUEST2 (children)
Aikaikkuna: baseline -12 months

questionnaire data: weekly number of days and daily duration of active travel to school and hobbies

baseline -12 months
Physical activity and sedentary behavior QUEST3 (children)
Aikaikkuna: baseline -12 months

questionnaire data: structured physical activity outside school hours

baseline -12 months
Physical activity and sedentary behavior QUEST4 (children)
Aikaikkuna: baseline -12 months

questionnaire data: unstructured physical activity outside school hours

baseline -12 months
Physical activity and sedentary behavior QUEST5 (children)
Aikaikkuna: baseline -12 months

questionnaire data: screen time and non-screen time sitting

baseline -12 months
Physical activity and sedentary behavior ACTIVITY1 (children)
Aikaikkuna: baseline -12 months

accelerometer data: daily number of steps

baseline -12 months
Physical activity and sedentary behavior ACTIVITY2 (children)
Aikaikkuna: baseline -12 months

accelerometer data: daily minutes of total and intensity-specific physical activity

baseline -12 months
Physical activity and sedentary behavior ACTIVITY3 (children)
Aikaikkuna: baseline -12 months

accelerometer data: daily minutes of stationary behavior

baseline -12 months
Physical activity and sedentary behavior ACTIVITY4 (children)
Aikaikkuna: baseline -12 months

accelerometer data: meeting physical activity recommendations

baseline -12 months
Physical activity and sedentary behavior ACTIVITY5 (children)
Aikaikkuna: baseline -12 months

accelerometer data: daily number of breaks in stationary behavior

baseline -12 months
Laboratory assessment of cardiovascular risk LIPIDS (children)
Aikaikkuna: baseline -12 months

lipids (total cholesterol, LDL, HDL, triglycerides; mmol/l)

baseline -12 months
Laboratory assessment of cardiovascular risk INFL (children)
Aikaikkuna: baseline -12 months

hs-CRP; mg/l

baseline -12 months
Laboratory assessment of cardiovascular risk HOMA (children)
Aikaikkuna: baseline -12 months

HOMA index calculated as glucose; mmol/l x insulin; mU/l / 22.5

baseline -12 months
Process evaluation: reach1
Aikaikkuna: baseline

participation rate of the families recruited (research database on study visits)

baseline
Process evaluation: reach2
Aikaikkuna: baseline

representativeness of the families participating (parents' and children's age, questionnaire on socio-economics)

baseline
Process evaluation: compliance1
Aikaikkuna: baseline -12 months

participation rate in measurements (number of study visits and questionnaires completed)

baseline -12 months
Process evaluation: compliance2
Aikaikkuna: baseline -12 months

proportion of sessions completed in the web-based portal (data accumulated in the web-based portal)

baseline -12 months
Process evaluation: acceptability1
Aikaikkuna: baseline -12 months

usefulness and ease of use (questionnaire and proportion of webportal sessions completed by the families)

baseline -12 months
Process evaluation: acceptability2
Aikaikkuna: baseline -12 months

credibility and satisfaction of the web-based portal (questionnaire and proportion of webportal sessions completed by the families)

baseline -12 months
Process evaluation: acceptability3
Aikaikkuna: baseline -12 months

occurrence of technical problems (questionnaire)

baseline -12 months

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Arterial wall thickness (mothers)
Aikaikkuna: baseline

intima-media thickness; common carotid, brachial and radial; mm

baseline
Left ventricular mass (mothers)
Aikaikkuna: baseline

left ventricular mass; g

baseline
Left ventricular systolic function (mothers)
Aikaikkuna: baseline

left ventricular global longitudinal strain; %

baseline
Left ventricular diastolic function LAV (mothers)
Aikaikkuna: baseline

left atrial volume; ml

baseline
Left ventricular diastolic function MVPWD (mothers)
Aikaikkuna: baseline

pulsed wave Doppler mitral early to late inflow velocity ratio (no unit)

baseline
Left ventricular diastolic function MVlatE (mothers)
Aikaikkuna: baseline

mitral lateral annular pulsed wave tissue Doppler early velocity; cm/s

baseline
Left ventricular diastolic function MVseptE (mothers)
Aikaikkuna: baseline

septal pulsed wave tissue Doppler early velocity; cm/s

baseline
Arterial wall thickness (children)
Aikaikkuna: baseline

intima-media thickness; common carotid, brachial and radial; mm

baseline
Left ventricular mass (children)
Aikaikkuna: baseline

left ventricular mass; g

baseline
Left ventricular systolic function (children)
Aikaikkuna: baseline

left ventricular global longitudinal strain; %

baseline
Left ventricular diastolic function LAV (children)
Aikaikkuna: baseline

left atrial volume; ml

baseline
Left ventricular diastolic function MVPWD (children)
Aikaikkuna: baseline

pulsed wave Doppler mitral early to late inflow velocity ratio (no unit)

baseline
Left ventricular diastolic function MVlatE (children)
Aikaikkuna: baseline

mitral lateral annular pulsed wave tissue Doppler early velocity; cm/s

baseline
Left ventricular diastolic function MVseptE (children)
Aikaikkuna: baseline

septal pulsed wave tissue Doppler early velocity; cm/s

baseline
Heart rate variability (mothers)
Aikaikkuna: baseline -12 months

standard deviation of all R-R intervals; root mean square of successive R-R interval differences, ms; High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2 ;Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2 ; and LF/HF ratio

baseline -12 months
Blood pressure 24 hour variability (children)
Aikaikkuna: baseline -12 months

nocturnal systolic and diastolic BP dip; standard deviation of systolic and diastolic BP; weighted standard deviation of systolic and diastolic BP; mmHg

baseline -12 months
HRV RR RMS (mothers)
Aikaikkuna: baseline - 12 months

root mean square of successive R-R interval differences, ms

baseline - 12 months
HRV RR HFP (mothers)
Aikaikkuna: baseline - 12 months

High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2

baseline - 12 months
HRV RR LFP (mothers)
Aikaikkuna: baseline - 12 months

Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2

baseline - 12 months
HRV LF/HF ratio (mothers)
Aikaikkuna: baseline - 12 months

LF/HF ratio

baseline - 12 months
HRV RR RMS (children)
Aikaikkuna: baseline - 12 months

root mean square of successive R-R interval differences, ms

baseline - 12 months
HRV RR HFP (children)
Aikaikkuna: baseline - 12 months

High frequency power of R-R intervals from spectral band 0.15-0.4 Hz, ms2

baseline - 12 months
HRV RR LFP (children)
Aikaikkuna: baseline - 12 months

Low frequency power of R-R intervals from spectral band 0.04-0.15 Hz, ms2

baseline - 12 months
HRV LF/HF ratio (children)
Aikaikkuna: baseline - 12 months

LF/HF ratio

baseline - 12 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Tiina Jääskeläinen, PhD, University of Helsinki
  • Opintojen puheenjohtaja: Hannele Laivuori, Prof, MD, University of Helsinki and University of Tampere
  • Opintojohtaja: Taisto Sarkola, PhD, MD, Helsinki University Central Hospital

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Lauantai 1. kesäkuuta 2019

Ensisijainen valmistuminen (Todellinen)

Torstai 31. elokuuta 2023

Opintojen valmistuminen (Todellinen)

Sunnuntai 31. joulukuuta 2023

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 7. joulukuuta 2020

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 14. joulukuuta 2020

Ensimmäinen Lähetetty (Todellinen)

Maanantai 21. joulukuuta 2020

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 2. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 28. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa